News | February 25, 2026
BNB Plus’ Biopharma subsidiary LineaRx lands major LineaDNA orders
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
If approved, DTX401 would be the first treatment to address the disease at its root cause
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
The new lineup features everything from the Color Fixation and Hair Therapy ranges to the Balanced Cleansing Shampoo and Nourishment & Protection Conditioner
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
Subscribe To Our Newsletter & Stay Updated
